BCPP common mistakes
BCPP · Understand the traps and how to avoid them.
Committing to a diagnosis or plan after finding one abnormal result (e.g., low TSH, positive urine drug screen, elevated PHQ-9) without completing a structured assessment of symptoms, timeline, medications, substance use, and medical history.
Pattern-recognition and anchoring bias under time pressure; the first salient data point feels like the answer and truncates further inquiry.
What to do instead
Use a fixed assessment checklist (chief complaint, onset/course, prior trials and response, current meds including OTC/supplements, substance use, medical comorbidity, labs, risk assessment) and verbalize each element before selecting an answer choice.
Treating a screening or rating scale score as a diagnosis, or failing to act on a specific item (e.g., ignoring the suicidality item on a depression scale, or treating a CIWA score as a reason to give a benzodiazepine without checking the trend and vital signs).
Superficial familiarity with scale names without knowing cutoffs, what each threshold triggers, and that scales screen or track severity rather than diagnose.
What to do instead
Memorize for each commonly used instrument: purpose, score ranges/cutoffs, what action each cutoff mandates, and its limitations; always pair the score with clinical interview and risk assessment.
Selecting the newest or most familiar antipsychotic/antidepressant by default instead of matching the agent to patient-specific factors such as prior response, metabolic and cardiac risk, formulation, interactions, and cost.
Recency and availability bias; drug names are memorized as lists rather than as profiles compared against patient variables.
What to do instead
Build and use a comparison grid (efficacy, key adverse effects, metabolic/QT risk, CYP interactions, formulation, cost, monitoring burden) and justify each selection with at least one explicit patient-specific factor.
Using subtherapeutic doses or stopping an antidepressant too early because of early side effects, without applying expected onset of benefit, target dose, titration schedule, and continuation/maintenance duration.
Conflating expected early tolerability effects with true intolerance, and not internalizing the 2-4 week onset and 6-8 week full-response timeline.
What to do instead
For each major drug class, know starting dose, target dose, titration interval, expected time to response, and minimum continuation duration; when a vignette shows early side effects, first consider dose timing/adjustment rather than discontinuation.
Missing clinically significant drug interactions when adding or removing an agent, especially CYP inducers/inhibitors (e.g., carbamazepine, fluoxetine, fluvoxamine, bupropion) and pharmacodynamic pairs (serotonergic agents, QT-prolonging drugs, sedatives).
Relying on memorized 'danger list' pairs instead of reasoning from mechanism, so interactions outside the memorized pairs are missed.
What to do instead
For every medication change, run a two-step check: mechanism-based pharmacokinetic (CYP induction/inhibition, protein binding) and pharmacodynamic (additive serotonergic, sedative, QT, anticholinergic, bleeding) interactions; state the mechanism and the monitoring plan.
Failing to apply mandatory monitoring at the correct interval for high-risk drugs (clozapine ANC, lithium level and renal/thyroid function, valproate LFTs/ammonia, antipsychotic metabolic panel, QT-prolonging agents).
Monitoring schedules are learned as isolated facts without anchoring them to baseline versus interval timing, so vignette timelines are misread.
What to do instead
Memorize a monitoring table with columns for baseline, frequency during titration, and maintenance interval; in each vignette, explicitly state when the last test was done and when the next is due.
Providing medication education that covers content but ignores health literacy, cost, stigma, side-effect expectations, and the patient's adherence barriers, and failing to confirm understanding with teach-back.
Counseling is treated as information transfer rather than a behavior-change intervention; adherence barriers are assumed rather than elicited.
What to do instead
Use a structured counseling script (indication, expected timeline, key side effects and what to do, missed-dose plan, cost/access plan) plus open-ended questions and teach-back; screen for cost, stigma, and regimen complexity before finalizing the plan.
Not documenting or communicating a recommendation in an actionable, team-ready format (no clear recommendation, rationale, monitoring plan, or follow-up), or making recommendations outside the pharmacist's scope without escalation.
Clinical reasoning is practiced in isolation from documentation and interprofessional communication, so the consult is clinically correct but operationally unusable.
What to do instead
Practice writing every consult in SBAR format: situation, background, assessment, specific recommendation with rationale, monitoring plan, and who will follow up; know when to escalate to the prescriber.
Treating statistical significance as clinical significance, miscomputing or misinterpreting ARR/NNT/NNH and confidence intervals, or misclassifying study design and level of evidence.
Weak biostatistics foundation and lack of deliberate practice with trial data; p-values are over-weighted relative to effect size and precision.
What to do instead
Drill calculations of ARR, RRR, NNT/NNH, and CI interpretation on abstract-level data; classify designs (RCT, cohort, case-control, meta-analysis) and apply a critical-appraisal checklist covering randomization, blinding, follow-up, and applicability.
Overgeneralizing trial findings to patient groups excluded from the study (older adults, pregnancy, hepatic/renal impairment, substance use) without checking external validity and pharmacokinetic changes.
Evidence is memorized as conclusions rather than as population-specific findings; applicability is assumed rather than assessed.
What to do instead
For each landmark finding, record the population studied, exclusion criteria, and dosing used; before applying it, state how the patient differs and what pharmacokinetic or monitoring adjustment follows.